Kiniksa Pharmaceuticals International (KNSA) Sales of Property, Plant and Equipment (2022)
Powered by 
Analysis
Kiniksa Pharmaceuticals International (KNSA) Sales of Property, Plant and Equipment (2022) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Sales of Property, Plant and Equipment (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | - |
| 10 | Kiniksa Pharmaceuticals International | 6.12 Bn | 5.60 Bn | 220.03 Mn | - |